Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Detailed price information for Veru Inc (VERU-Q) from The Globe and Mail including charting and trades.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

(MENAFN- GlobeNewsWire - Nasdaq) MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines ...

Veru's experimental drug helps older obese patients on Wegovy preserve muscle January 27, 2025 Akero Therapeutics shares gained 117% in early trading on Monday, after its lead drug showed it can ...

Europe to review safety data for Eisai-Biogen Alzheimer's drug January 31, 2025 Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy ...